RNA-loaded dendritic cell vaccine

An RNA-loaded dendritic cell vaccine is a personalized, autologous cancer immunotherapy in which a patient's own dendritic cells are harvested and then loaded ex vivo with messenger RNA (mRNA) or total tumor-derived RNA encoding tumor-associated antigens. The modified dendritic cells are then re-infused into the patient to stimulate an immune response against cancer cells. The mechanism of action involves the presentation of multiple antigenic epitopes by the engineered DCs to both CD8+ and CD4+ T-cells, thereby inducing robust cellular immunity targeting both characterized and uncharacterized tumor antigens. Some advanced versions also include co-electroporation with RNAs encoding driver mutations or overexpressed non-mutated antigens for highly personalized therapy. This approach is being investigated primarily for various cancers including malignant glioma, diffuse intrinsic pontine glioma, WHO grade III glioma, metastatic uveal melanoma, pancreatic adenocarcinoma, and renal cell carcinoma[1][3][4][5][6][7].

Other names

total tumor RNA-loaded dendritic cell vaccinemRNA-loaded dendritic cell vaccinetumor RNA loaded dendritic cell immunotherapy